
“The quality and coverage of B2B contact database are very impressive...”
Mark J.
`
+27
Beam Therapeutics, launched in 2018, is pioneering the use of CRISPR base editing to develop a broad portfolio of advanced genetic medicines. Our groundbreaking base editing technology allows us to make permanent, specific edits to single bases in DNA and RNA, without cutting the strands. Base editor therapeutics represent a new class of precision genetic medicines, combining precision targeting of the genome with precision control of editing outcomes. Our dream is to provide life-long cures for patients suffering from serious diseases. The Beam Team Is: A community of fearless innovators Rigorous and honest in our research Listening with open minds...
Gene therapy,base editing,gene editing,precision medicines,crispr,crispr cas9,genetic diseases,rare diseases,hematology,lipid nanoparticles,lnp,vector production,aav,in vivo,ex vivo,liver,mrna production,mrna,dna,rna,cas9,drug development,drug delivery,immunology,formulation development,virology,viral delivery,nanoparticles formulation,structural biology,cell biology,protein sciences,and cell therapy
Beam therapeutics operates in the Biotechnology research industry.
Beam therapeutics's revenue is 101m - 500m
Beam therapeutics has 501 - 1000 employees.
Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.
Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.
Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.